- Home
- MGEE vs APLS Comparison
MGEE vs APLS Comparison
Compare MGEE & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGEE
- APLS
- Stock Information
- Founded
- MGEE 1855
- APLS 2009
- Country
- MGEE United States
- APLS United States
- Employees
- MGEE N/A
- APLS N/A
- Industry
- MGEE Electric Utilities: Central
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- MGEE Energy
- APLS Health Care
- Exchange
- MGEE Nasdaq
- APLS Nasdaq
- Market Cap
- MGEE 3.1B
- APLS 3.5B
- IPO Year
- MGEE N/A
- APLS 2017
- Fundamental
- Price
- MGEE $87.74
- APLS $27.97
- Analyst Decision
- MGEE Sell
- APLS Buy
- Analyst Count
- MGEE 1
- APLS 20
- Target Price
- MGEE $74.00
- APLS $34.11
- AVG Volume (30 Days)
- MGEE 140.0K
- APLS 3.0M
- Earning Date
- MGEE 08-06-2025
- APLS 07-31-2025
- Dividend Yield
- MGEE 2.06%
- APLS N/A
- EPS Growth
- MGEE 12.86
- APLS N/A
- EPS
- MGEE 3.60
- APLS N/A
- Revenue
- MGEE $701,317,000.00
- APLS $754,649,000.00
- Revenue This Year
- MGEE $10.77
- APLS $10.84
- Revenue Next Year
- MGEE $3.48
- APLS $10.51
- P/E Ratio
- MGEE $24.22
- APLS N/A
- Revenue Growth
- MGEE 8.61
- APLS 20.02
- 52 Week Low
- MGEE $82.21
- APLS $16.10
- 52 Week High
- MGEE $109.22
- APLS $41.94
- Technical
- Relative Strength Index (RSI)
- MGEE 59.37
- APLS 74.59
- Support Level
- MGEE $84.10
- APLS $26.23
- Resistance Level
- MGEE $86.17
- APLS $28.87
- Average True Range (ATR)
- MGEE 1.66
- APLS 1.07
- MACD
- MGEE 0.40
- APLS 0.18
- Stochastic Oscillator
- MGEE 96.63
- APLS 84.04
About MGEE MGE Energy Inc
MGE Energy provides electric service to 161,000 customers and natural gas service to 173,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings. MGE's generation mix is 40% coal, 21% renewable energy, 17% natural gas, and third-party purchased power.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.